These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 18982740)

  • 41. High hepatitis C virus prevalence and incidence among Canadian intravenous drug users.
    Roy E; Alary M; Morissette C; Leclerc P; Boudreau JF; Parent R; Rochefort J; Claessens C;
    Int J STD AIDS; 2007 Jan; 18(1):23-7. PubMed ID: 17326858
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of sex, hygiene and drug equipment sharing with hepatitis C virus infection among non-injecting drug users in New York City.
    Howe CJ; Fuller CM; Ompad DC; Galea S; Koblin B; Thomas D; Vlahov D
    Drug Alcohol Depend; 2005 Sep; 79(3):389-95. PubMed ID: 16102381
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004.
    Hickman M; Hope V; Brady T; Madden P; Jones S; Honor S; Holloway G; Ncube F; Parry J
    J Viral Hepat; 2007 Sep; 14(9):645-52. PubMed ID: 17697017
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Seroprevalence of HBV, HCV and HIV infection among intravenous drug users in Shahr-e-Kord, Islamic Republic of Iran.
    Imani R; Karimi A; Rouzbahani R; Rouzbahani A
    East Mediterr Health J; 2008; 14(5):1136-41. PubMed ID: 19161086
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Seroprevalence of hepatitis C among a juvenile detention population.
    Feldman GM; Sorvillo F; Cole B; Lawrence WA; Mares R
    J Adolesc Health; 2004 Dec; 35(6):505-8. PubMed ID: 15581531
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Study on the relationship between hepatitis C virus infection and sharing injection equipment, sexual behavior among injecting drug users].
    Zhou F; Ma ZE; Hu W; Feng ZL; Chen KL; Qin GM; Sun Q; Liu G; Liang S; He YX; Liu SZ; Ruan YH; Shao YM
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Apr; 25(4):329-32. PubMed ID: 15231203
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack.
    Macías J; Palacios RB; Claro E; Vargas J; Vergara S; Mira JA; Merchante N; Corzo JE; Pineda JA
    Liver Int; 2008 Jul; 28(6):781-6. PubMed ID: 18312289
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatitis C virus infection in South Australian prisoners: seroprevalence, seroconversion, and risk factors.
    Miller ER; Bi P; Ryan P
    Int J Infect Dis; 2009 Mar; 13(2):201-8. PubMed ID: 18790659
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Risks incurred by the first intravenous drug injection].
    Varescon I; Vidal-Trécan G; Gagnière B; Christoforov B; Boissonnas A
    Ann Med Interne (Paris); 2000 Oct; 151 Suppl B():B5-8. PubMed ID: 11221691
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Injecting and sexual risk behaviours, sexually transmitted infections and HIV prevalence in injecting drug users in three states in India.
    Mahanta J; Medhi GK; Paranjape RS; Roy N; Kohli A; Akoijam BS; Dzuvichu B; Das HK; Goswami P; Thongamba G;
    AIDS; 2008 Dec; 22 Suppl 5():S59-68. PubMed ID: 19098480
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modelling the hepatitis C virus epidemic in Australia.
    Razali K; Thein HH; Bell J; Cooper-Stanbury M; Dolan K; Dore G; George J; Kaldor J; Karvelas M; Li J; Maher L; McGregor S; Hellard M; Poeder F; Quaine J; Stewart K; Tyrrell H; Weltman M; Westcott O; Wodak A; Law M
    Drug Alcohol Depend; 2007 Dec; 91(2-3):228-35. PubMed ID: 17669601
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Estimating the force of infection for HCV in injecting drug users using interval-censored data.
    Castro-Sánchez A; Shkedy Z; Hens N; Aerts M; Geskus R; Prins M; Wiessing L; Kretzschmar M
    Epidemiol Infect; 2012 Jun; 140(6):1064-74. PubMed ID: 21910930
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004.
    Amon JJ; Garfein RS; Ahdieh-Grant L; Armstrong GL; Ouellet LJ; Latka MH; Vlahov D; Strathdee SA; Hudson SM; Kerndt P; Des Jarlais D; Williams IT
    Clin Infect Dis; 2008 Jun; 46(12):1852-8. PubMed ID: 18462109
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The impact of changes to heroin supply on blood-borne virus notifications and injecting related harms in New South Wales, Australia.
    Day C; Degenhardt L; Gilmour S; Hall W
    BMC Public Health; 2005 Aug; 5():84. PubMed ID: 16102177
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HCV seroconversion among never-injecting heroin users at baseline: no predictors identified other than starting injection.
    Bravo MJ; Vallejo F; Barrio G; Brugal MT; Molist G; Pulido J; Sordo L; de la Fuente L;
    Int J Drug Policy; 2012 Sep; 23(5):415-9. PubMed ID: 22421554
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevalence and correlates of suicidal ideation among young injection vs. noninjection drug users.
    Havens JR; Sherman SG; Sapun M; Strathdee SA
    Subst Use Misuse; 2006; 41(2):245-54. PubMed ID: 16393745
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Seroprevalence of hepatitis C in intravenous opioid users presenting in the early phase of injecting drug use in Singapore.
    Winslow M; Subramaniam M; Ng WL; Lee A; Song G; Chan YH
    Singapore Med J; 2007 Jun; 48(6):504-8. PubMed ID: 17538746
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study.
    Vickerman P; Hickman M; Judd A
    Int J Epidemiol; 2007 Apr; 36(2):396-405. PubMed ID: 17218325
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection.
    Hagan H; Des Jarlais DC; Stern R; Lelutiu-Weinberger C; Scheinmann R; Strauss S; Flom PL
    Int J Drug Policy; 2007 Oct; 18(5):341-51. PubMed ID: 17854721
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Perceived barriers to safe-injection practices among drug injectors who remain HCV-negative.
    Stein MD; Dubyak P; Herman D; Anderson BJ
    Am J Drug Alcohol Abuse; 2007; 33(4):517-25. PubMed ID: 17668337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.